Selicrelumab
- Generic Name
- Selicrelumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1622140-49-1
- Unique Ingredient Identifier
- 0O39RGI33V
- Background
Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 4
- Registration Number
- NCT03892525
- Locations
- 🇫🇷
APHP - Hôpital Henri Mondor, Créteil, France
🇫🇷CHU de Rennes - Hôpital Pontchaillou, Rennes, France
🇫🇷CHU de Montpellier, Montpellier, France
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT03555149
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- Drug: CapecitabineDrug: AtezolizumabDrug: Ribociclib (dose #1)Drug: Inavolisib (dose #2)Drug: AbemaciclibDrug: Trastuzumab DeruxtecanDrug: IpatasertibDrug: Sacituzumab GovitecanDrug: FulvestrantDrug: Ribociclib (dose #2)Drug: Inavolisib (dose #1)Drug: SGN-LIV1ADrug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug: TocilizumabDrug: BevacizumabDrug: LetrozoleDrug: Nab-PaclitaxelDrug: InavolisibDrug: Selicrelumab
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 340
- Registration Number
- NCT03193190
- Locations
- 🇺🇸
Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 94
- Registration Number
- NCT02665416
- Locations
- 🇳🇱
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
🇪🇸Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT02304393
- Locations
- 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇨🇦University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
🇨🇦Jewish General Hospital / McGill University, Montreal, Quebec, Canada
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
- First Posted Date
- 2009-11-05
- Last Posted Date
- 2015-09-24
- Target Recruit Count
- 22
- Registration Number
- NCT01008527
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.